abstract |
The present invention relates to novel heterocyclyl compounds of formula (I) and physiologically acceptable salts thereof. Such compounds are antagonists of the CCR2 receptor, CCR5 receptor and / or CCR3 receptor and can be used as medicaments: Formula I Where A, X, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , m, n and p are as defined in the specification and claims. |